NASDAQ:PRNB Principia Biopharma (PRNB) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free PRNB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$100.05▼$100.0550-Day Range$99.95▼$100.2752-Week Range$25.35▼$101.89VolumeN/AAverage Volume729,676 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Principia Biopharma alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Principia Biopharma Stock (NASDAQ:PRNB)Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. PRNB Stock News HeadlinesMay 28, 2023 | bizjournals.comPrincipia College names new presidentMay 5, 2023 | theguardian.comCBI appoints ethics consultancy Principia Advisory in fight for survivalApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 22, 2023 | benzinga.comTruist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price TargetJanuary 17, 2023 | msn.comWooly mammoth tusk discovered on Principia College campusOctober 12, 2022 | finance.yahoo.comDodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ CapabilitiesOctober 1, 2022 | sfgate.comPrincipia earns top US News & World Report ratingJuly 7, 2022 | investing.comPrincipia Biopharma Inc (PRNB)April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 5, 2022 | chron.comDance therapy: In-person performances back at PrincipiaMarch 18, 2022 | msn.comWhere to find the Golden Order Principia in Elden RingJanuary 10, 2022 | news.yahoo.comLebanon's Skobel signs with PrincipiaOctober 1, 2021 | chron.comPrincipia College earns honorsJuly 31, 2021 | nasdaq.comPrincipia Biopharma Inc. Common Stock (PRNB)See More Headlines Receive PRNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRNB CUSIPN/A CIKN/A Webwww.principiabio.com Phone650-416-7700FaxN/AEmployees65Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.08% Return on Assets-21.11% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$35.16 million Price / Sales94.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.14Miscellaneous Outstanding Shares33,209,000Free FloatN/AMarket Cap$3.32 billion OptionableNot Optionable Beta0.86 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Alan B. Colowick Ph.D. (Age 57)M.D., M.P.H., Exec. Chairman Mr. Martin Babler (Age 54)CEO & Director Mr. Christopher Y. Chai (Age 52)Chief Financial Officer Ms. Stefani A. Wolff (Age 57)Chief Devel. Officer Dr. David M. Goldstein (Age 53)Chief Scientific Officer Key CompetitorsBiohavenNYSE:BHVNAxsome TherapeuticsNASDAQ:AXSMHUTCHMEDNASDAQ:HCMAmicus TherapeuticsNASDAQ:FOLDBausch Health CompaniesNYSE:BHCView All Competitors PRNB Stock Analysis - Frequently Asked Questions How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc. (NASDAQ:PRNB) announced its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of ($1.03) by $1.34. The company earned $50 million during the quarter, compared to analyst estimates of $50 million. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), VBI Vaccines (VBIV), ImmunoGen (IMGN) and Taiwan Semiconductor Manufacturing (TSM). When did Principia Biopharma IPO? Principia Biopharma (PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. This page (NASDAQ:PRNB) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Principia Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.